Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy -: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

被引:185
|
作者
Gerdts, E [1 ]
Oikarinen, L
Palmieri, V
Otterstad, JE
Wachtell, K
Boman, K
Dahlöf, B
Devereux, RB
机构
[1] Haukeland Hosp, Dept Heart Dis, N-5021 Bergen, Norway
[2] Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland
[3] Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA
[4] Vestfold Cent Hosp, Dept Med, Tonsberg, Norway
[5] Copenhagen Cty Univ Hosp, Dept Med, Glostrup, Denmark
[6] Skellefteaa Hosp, Dept Med, Skellefteaa, Sweden
[7] Umea Univ, Skellefteaa, Sweden
[8] Sahlgrens Univ Hosp, Dept Med, Gothenburg, Sweden
关键词
left atrial size; hypertrophy; age; body mass index;
D O I
10.1161/hy0302.105683
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Left ventricular hypertrophy has been suggested to mediate the relation between hypertension and left atrial enlargement, with associated risks of atrial fibrillation and stroke. However, less is known about correlates of left atrial size in hypertensive patients with left ventricular hypertrophy. We assessed left atrial size by echo cardiography in 941 hypertensive patients, age 55 to 80 (mean, 66) years, with electrocardiographic left ventricular hypertrophy at baseline in the Losartan Intervention For Endpoint reduction in hypertension study. Enlarged left atrial diameter (women, >3.8 cm; men, >4.2 cm) was present in 56% of women and 38% of men (P < 0.01). Compared with the 512 patients with normal left atrial size, the 429 patients with enlarged left atrium more often had mitral regurgitation, atrial fibrillation, and echocardiographic left ventricular hypertrophy. They also had higher age, systolic blood pressure, pulse pressure, weight, body mass index, left ventricular internal chamber dimension, stroke volume, and mass and lower relative wall thickness and ejection fraction (ail, P < 0.05). In logistic regression analysis, left atrial enlargement was related to left ventricular hypertrophy and eccentric geometry; greater body mass index, systolic blood pressure, and age; female gender; mitral regurgitation; and atrial fibrillation (all, P < 0.05). Thus, left atrial size in hypertensive patients with electrocardiographic left ventricular hypertrophy is influenced by gender, age, obesity, systolic blood pressure, and left ventricular geometry independently of left ventricular mass and presence of mitral regurgitation or atrial fibrillation.
引用
收藏
页码:739 / 743
页数:5
相关论文
共 50 条
  • [21] Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study
    Olsen, Michael Hecht
    Wachtell, Kristian
    Beevers, Gareth
    Dahlof, Bjorn
    Devereux, Richard B.
    de Faire, Ulf
    Fyhrquist, Frej
    Ibsen, Hams
    Kjeldsen, Sverre E.
    Lederhalle-Pedersen, Ole
    Lindholm, Lars H.
    Narayan, Puneet
    Nieminen, Markku S.
    Omvik, Per
    Opard, Suzanne
    Wedel, Hans
    AMERICAN HEART JOURNAL, 2009, 157 (01) : 177 - 184
  • [22] The interaction between aspirin and losartan on cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy. A losartan intervention for endpoint reduction (LIFE) substudy
    Fossum, E
    Kjeldsen, SE
    Dahlof, B
    Devereux, RB
    Julius, S
    Snapinn, S
    AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (05) : 11A - 12A
  • [23] The interaction between aspirin and losartan on cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy.: A losartan intervention for endpoint reduction (life) substudy
    Fossum, E
    Kjeldsen, SE
    Dahlöf, B
    Devereux, RB
    Julius, S
    Snappin, S
    JOURNAL OF HYPERTENSION, 2003, 21 : S118 - S118
  • [24] Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients:: The Losartan Intervention For Endpoint Reduction (LIFE) study
    Oikarinen, L
    Nieminen, MS
    Toivonen, L
    Viitasalo, M
    Wachtell, K
    Papademetriou, V
    Jern, S
    Dahlöf, B
    Devereux, RB
    Okin, PM
    AMERICAN HEART JOURNAL, 2003, 145 (05) : 919 - 925
  • [25] A Point System Table to Estimate the Risk of Cardiovascular Events in Patients With Hypertension and Left Ventricular Hypertrophy. The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study
    Hille, Darcy
    Kjeldsen, Sverre E.
    Dahloef, Bjoern
    Edelman, Jonathan M.
    Devereux, Richard B.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (10) : A214 - A214
  • [26] Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function:: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study
    Wachtell, K
    Papademetriou, V
    Smith, G
    Gerdts, E
    Dahlöf, B
    Engblom, E
    Aurigemma, GP
    Bella, JN
    Ibsen, H
    Rokkedal, J
    Devereux, RB
    AMERICAN HEART JOURNAL, 2004, 148 (03) : 538 - 544
  • [27] Losartan for LIFE in hypertension with left ventricular hypertrophy?
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (01) : 115 - 118
  • [28] Losartan-based versus atenolol-based therapy in patients with hypertension and left ventricular hypertrophy: An economic evaluation of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study for Germany
    Krobot, K. J.
    Carides, G. W.
    Wagner, A.
    Burke, T. A.
    VALUE IN HEALTH, 2006, 9 (06) : A353 - A353
  • [29] Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The losartan intervention for endpoint reduction in hypertension (LIFE) Trial - Letter regarding article by Devereux et al.
    O'Rourke, MF
    Safar, ME
    CIRCULATION, 2005, 111 (22) : E377 - E377
  • [30] Left atrial systolic force in hypertensive patients with left ventricular hypertrophy:: the LIFE study
    Chinali, Marcello
    de Simone, Giovanni
    Wachtell, Kristian
    Gerdts, Eva
    Gardin, Julius M.
    Boman, Kurt
    Nieminen, Markku S.
    Papademetriou, Vasilios
    Dahlof, Bjorn
    Devereux, Richard B.
    JOURNAL OF HYPERTENSION, 2008, 26 (07) : 1472 - 1476